Pharmaids Pharmaceuticals Hits 52-Week Low with Strong Sell Rating from MarketsMOJO
Pharmaids Pharmaceuticals, a microcap company in the pharmaceuticals and drugs industry, has hit a 52-week low on October 25th, 2024. MarketsMojo has given it a Strong Sell rating. The stock has underperformed the sector by -2.54% and is currently trading below its moving averages. In the past year, it has seen a negative return of -31.99%. Investors should monitor its performance closely.
Pharmaids Pharmaceuticals, a microcap company in the pharmaceuticals and drugs industry, has recently hit a 52-week low on October 25th, 2024. This news has been accompanied by a "Strong Sell" rating from MarketsMOJO, a leading stock analysis platform.
The stock price of Pharmaids Pharmaceuticals has been on a downward trend, with today's price hitting a low of Rs. 32.5. In comparison to the sector, the stock has underperformed by -2.54%. This marks the fourth consecutive day of losses for the company, with a total decline of -14.45% in this period.
Furthermore, Pharmaids Pharmaceuticals is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend in the stock.
In the past year, Pharmaids Pharmaceuticals has seen a negative return of -31.99%, while the Sensex has shown a positive return of 24.31%. This further highlights the underperformance of the company in the market.
While there has been no mention of future potential or investor interest, the current state of Pharmaids Pharmaceuticals' stock is a cause for concern. With a "Strong Sell" rating and a continuous decline in stock price, investors may want to closely monitor the company's performance in the coming days.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
